A free alternative to Citeline and Evaluate

Every drug in development for any disease, target or company: who owns it, how far it has got and what happens next. Free to start, $49 a month for everything. No sales call.

openlandscape.app

Obesity

95 of 101 checked · data updated 18 Nov 2026

Approved10Filed3Phase 331Phase 257
DrugHow it worksCompanyStageNext dateTrials
GIP + GLP-1
Eli Lilly · Public LLY
Approved Nov 2026soonPhase 3 trial completes 19 trials
Amylin + GLP-1
Novo Nordisk · Public NVO
Filed Dec 2026US FDA decision expected in Q4 2026 (company guidance, exact date not public) 4 trials
GIP + GLP-1 + glucagon
Eli Lilly · Public LLY
Phase 3 Nov 2026soonPhase 3 trial completes 6 trials
—
Phase 3 31 Dec 2026Phase 3 trial completes 1 trial
NLRP3 inhibitor unconfirmed
BioAge Labs · Public BIOA
Phase 2 30 Nov 2026soonPhase 2 trial completes 1 trial

OpenLandscape vs Citeline, Evaluate and Cortellis

Every drug in development and its trials, without the annual contract or the sales call. For sales forecasts and deal values, the big databases are still the right tool.

OpenLandscapeCiteline, Evaluate, Cortellis
Price$0 to start, $49 a monthPrice on request
Free planYes—
ContractMonthly, cancel any timeAnnual contract
Getting startedSign up with your email, todayA sales call first
Every drug in development, by disease, target or companyYesYes
Trials, readouts and FDA and EMA decisionsYesYes
Where the data comes fromPublic registries, a link on every rowPublic sources plus their own research
Open sourceYes—
Sales forecasts, deal values and analyst notes—Yes

An alternative to Pharmaprojects, Trialtrove, Biomedtracker and Cortellis

What each is for, and what you get in OpenLandscape instead.

  • PharmaprojectsCiteline · Drug pipelines
    Covered

    Every drug in active trials for a disease, target or company, with its owner and stage.

  • TrialtroveCiteline · Clinical trials
    Covered

    The trials behind each drug, from ClinicalTrials.gov and the EU register.

  • BiomedtrackerCiteline · Catalysts and approval odds
    Partly

    The next readouts and FDA and EMA dates on every list, and an email when they change. No approval odds.

  • CortellisClarivate · Pipelines, deals and regulatory
    Partly

    Pipelines, trials and regulator decisions in one place. No deal values.

Questions about switching from Citeline

Is there a free alternative to Citeline?

Yes. OpenLandscape lists every drug in development for a disease, target or company, read from public registries every day, with a source on every row. Free shows the top 10 of any list and one landscape in full, with no payment card. Solo is $49 a month for every list in full, downloads and alerts.

How much do Citeline and Evaluate Pharma cost?

Neither shows a price: both are sold on annual contracts, with the price on request. OpenLandscape is free to start and $49 a month before VAT, and you can cancel any time.

Is OpenLandscape as complete as Citeline?

For drugs in clinical trials, it reads the public registries and regulators every day. It does not have sales forecasts, deal values, analyst notes, or preclinical drugs that are not yet in a registry. 207 drugs are checked by hand; the rest are grouped automatically from registry names and marked "not checked yet".

Where does the data come from?

ClinicalTrials.gov, the EU Clinical Trials register, FDA, EMA and SEC filings, and company press releases where a registry has not caught up. Every row links to the record it came from.

Can I export to Excel?

Yes, on Solo. Every list downloads as a CSV file that opens in Excel.

Can I use it from ChatGPT or Claude?

Yes. Add the OpenLandscape connector and ask about any drug, company or trial; answers come with their sources. Free includes 25 questions a month.

Who uses it?

Business development and competitive intelligence people at small and mid-size biotechs, consultants who build landscapes for clients, and investors. If you need forecasts or deal values, the big databases are still the right tool.

Build your competitive landscape, free

Search any disease, drug, target or company. One landscape in full is free, for good.